Plasma sphingomyelin (SM), an established biomarker of white matter hyperintensity (WMH), has recently been implicated in Alzheimer's disease (AD) risk, but its role in cognitive decline remains unclear.
Objective
To examine whether plasma SM (d18:1/24:0) is associated with incident AD risk and to clarify its relationships with AD pathology, neuroimaging, and cognition in non-demented adults.
Methods
We included 476 non-demented participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Kaplan-Meier analysis assessed AD progression, with group comparisons by log-rank test. Cox proportional hazards models estimated hazard ratios and 95% confidence intervals. Multiple linear regression and mixed-effects models evaluated associations of SM with cerebrospinal fluid biomarkers, neuroimaging measures, and cognition. A causal mediation analysis was performed using 10,000 bootstrapped iterations to evaluate the intermediary role of AD pathology in cognitive function.
Results
Participants with higher levels of SM (d18:1/24:0) exhibited decreased AD risk. Plasma SM (d18:1/24:0) presented positive associations with Rey Auditory Verbal Learning Test (RAVLT-immediate), amyloid-β pathology, 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism and brain volume, and negative associations with tau pathology, WMH-V, and ventricular volume. The association between SM (d18:1/24:0) and verbal memory was partially mediated by amyloid and tau pathology, FDG-PET, and hippocampal-V.
Conclusions
This study suggests that lower plasma SM (d18:1/24:0) levels are associated with an increased risk of AD. Plasma SM (d18:1/24:0) is closely related to cognitive performance, neuroimaging markers, and AD pathology, and its association with verbal memory may be partially mediated by AD pathology.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
2.
IsaacsonRSGanzerCAHristovH, et al.The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach. Alzheimers Dement2018; 14: 1663–1673.
3.
MortamaisMAshJAHarrisonJ, et al.Detecting cognitive changes in preclinical Alzheimer's disease: a review of its feasibility. Alzheimers Dement2017; 13: 468–492.
4.
El GaamouchFJingPXiaJ, et al.Alzheimer's disease risk genes and lipid regulators. J Alzheimers Dis2016; 53: 15–29.
5.
ZvěřováM. Clinical aspects of Alzheimer's disease. Clin Biochem2019; 72: 3–6.
6.
TajimaYIshikawaMMaekawaK, et al.Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis2013; 12: 68.
7.
TanziREBertramL. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell2005; 120: 545–555.
8.
PenkeBBogárFFülöpL. β-amyloid and the pathomechanisms of Alzheimer's disease: a comprehensive view. Molecules2017; 22: 1692.
9.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
10.
JackCRJrAndrewsSJBeachTG, et al.Revised criteria for the diagnosis and staging of Alzheimer's disease. Nat Med2024; 30: 2121–2124.
11.
WardlawJMSmithCDichgansM. Small vessel disease: mechanisms and clinical implications. Lancet Neurol2019; 18: 684–696.
12.
AgrawalSSchneiderJA. Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults. Cereb Circ Cogn Behav2022; 3: 100148.
13.
ArfanakisKEviaAMLeurgansSE, et al.Neuropathologic correlates of white matter hyperintensities in a community-based cohort of older adults. J Alzheimers Dis2020; 73: 333–345.
14.
BoylePAYuLFleischmanDA, et al.White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in old age. Ann Clin Transl Neurol2016; 3: 791–800.
15.
RizviBLaoPJChesebroAG, et al.Association of regional white matter hyperintensities with longitudinal Alzheimer-like pattern of neurodegeneration in older adults. JAMA Netw Open2021; 4: e2125166.
16.
MoscosoARey-BretalDSilva-RodríguezJ, et al.White matter hyperintensities are associated with subthreshold amyloid accumulation. Neuroimage2020; 218: 116944.
17.
GreenbergSMBacskaiBJHernandez-GuillamonM, et al.Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol2020; 16: 30–42.
18.
AzizkhanianIShethSAIavaroneAT, et al.Plasma lipid profiling identifies biomarkers of cerebral microvascular disease. Front Neurol2019; 10: 950.
19.
GiussaniPPrinettiATringaliC. The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders. J Neurochem2021; 156: 403–414.
20.
BrownDALondonE. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol1998; 14: 111–136.
21.
CzubowiczKJęśkoHWencelP, et al.The role of ceramide and sphingosine-1-phosphate in Alzheimer's disease and other neurodegenerative disorders. Mol Neurobiol2019; 56: 5436–5455.
SessaLNardielloAMSantoroJ, et al.Hydroxylated fatty acids: the role of the sphingomyelin synthase and the origin of selectivity. Membranes (Basel)2021; 11: 787.
24.
LiDMisialekJRHuangF, et al.Independent association of plasma hydroxysphingomyelins with physical function in the Atherosclerosis Risk in Communities (ARIC) Study. J Gerontol A Biol Sci Med Sci2018; 73: 1103–1110.
25.
LiDMisialekJRJackCR, et al.Plasma metabolites associated with brain MRI measures of neurodegeneration in older adults in the Atherosclerosis Risk in Communities-Neurocognitive Study (ARIC-NCS). Int J Mol Sci2019; 20: 1744.
26.
MapstoneMCheemaAKFiandacaMS, et al.Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med2014; 20: 415–418.
27.
DakterzadaFJovéMHuertoR, et al.Changes in plasma neutral and ether-linked lipids are associated with the pathology and progression of Alzheimer's disease. Aging Dis2023; 14: 1728–1738.
28.
HanXRozenSBoyleSH, et al.Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One2011; 6: e21643.
29.
MielkeMMBandaruVVHaugheyNJ, et al.Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging2010; 31: 17–24.
30.
RajanMRSotakMBarrenäsF, et al.Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Sci Rep2019; 9: 15385.
31.
SlizEShinJAhmadS, et al.Circulating metabolome and white matter hyperintensities in women and men. Circulation2022; 145: 1040–1052.
32.
MoseholmKFCronjéHTKochM, et al.Circulating sphingolipids in relation to cognitive decline and incident dementia: the Cardiovascular Health Study. Alzheimers Dement (Amst)2024; 16: e12623.
33.
CieriFZhuangXCordesD, et al.Relationship of sex differences in cortical thickness and memory among cognitively healthy subjects and individuals with mild cognitive impairment and Alzheimer disease. Alzheimers Res Ther2022; 14: 36.
34.
HallabA. Sleep and nighttime behavior disorders in older adults: associations with hypercholesterolemia and hypertriglyceridemia at baseline, and a predictive analysis of incident cases at 12 months follow-up. Lipids Health Dis2024; 23: 320.
35.
AisenPSPetersenRCDonohueM, et al.Alzheimer's disease neuroimaging initiative 2 clinical core: progress and plans. Alzheimers Dement2015; 11: 734–739.
36.
MaLZHuHWangZT, et al.P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders. Alzheimers Res Ther2021; 13: 200.
HanssonOSeibylJStomrudE, et al.CSF Biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement2018; 14: 1470–1481.
39.
Suárez-CalvetMMorenas-RodríguezEKleinbergerG, et al.Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener2019; 14: 1.
40.
ShengZWangLChenM, et al.Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia-astrocyte communication in Alzheimer's disease. Alzheimers Res Ther2025; 17: 2.
41.
OuYNXuWLiJQ, et al.FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study. Alzheimers Res Ther2019; 11: 57.
42.
QuYTanCCShenXN, et al.Association of plasma neurofilament light with small vessel disease burden in nondemented elderly: a longitudinal study. Stroke2021; 52: 896–904.
43.
WeinerMWVeitchDPAisenPS, et al.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement2015; 11: e1–120.
WangYLChenWCaiWJ, et al.Associations of white matter hyperintensities with cognitive decline: a longitudinal study. J Alzheimers Dis2020; 73: 759–768.
46.
LiXLWangRTTanCC, et al.Systolic blood pressure variability in late-life predicts cognitive trajectory and risk of Alzheimer's disease. Front Aging Neurosci2024; 16: 1448034.
47.
HochbergYBenjaminiY. More powerful procedures for multiple significance testing. Stat Med1990; 9: 811–818.
48.
ImaiKKeeleLTingleyD. A general approach to causal mediation analysis. Psychol Methods2010; 15: 309–334.
49.
NaudíACabréRJovéM, et al.Lipidomics of human brain aging and Alzheimer's disease pathology. Int Rev Neurobiol2015; 122: 133–189.
50.
ToledoJBArnoldMKastenmüllerG, et al.Metabolic network failures in Alzheimer's disease: a biochemical road map. Alzheimers Dement2017; 13: 965–984.
51.
BaloniPArnoldMBuitragoL, et al.Multi-omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. Commun Biol2022; 5: 1074.
52.
MosconiLDe SantiSLiY, et al.Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging2006; 33: 210–221.
53.
MielkeMMHaugheyNJBandaruVV, et al.Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis2011; 27: 259–269.
54.
NormanECutlerRGFlanneryR, et al.Plasma membrane sphingomyelin hydrolysis increases hippocampal neuron excitability by sphingosine-1-phosphate mediated mechanisms. J Neurochem2010; 114: 430–439.
55.
ZhangXLiuWCaoY, et al.Hippocampus proteomics and brain lipidomics reveal network dysfunction and lipid molecular abnormalities in APP/PS1 mouse model of Alzheimer's disease. J Proteome Res2020; 19: 3427–3437.
56.
ChoiSSniderAJ. Sphingolipids in high fat diet and obesity-related diseases. Mediators Inflamm2015; 2015: 520618.
57.
GreenCDMaceykaMCowartLA, et al.Sphingolipids in metabolic disease: the good, the bad, and the unknown. Cell Metab2021; 33: 1293–1306.
58.
SindhuSLeungYHArefanianH, et al.Neutral sphingomyelinase-2 and cardiometabolic diseases. Obes Rev2021; 22: e13248.
59.
Di PaoloGKimTW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci2011; 12: 284–296.
60.
ChuaXYTortaFChongJR, et al.Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer's disease and vascular dementia. Alzheimers Res Ther2023; 15: 214.
61.
KoalTKlavinsKSeppiD, et al.Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels. J Alzheimers Dis2015; 44: 1193–1201.
62.
FabeloNMartínVMarínR, et al.Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions. Neurobiol Aging2014; 35: 1801–1812.
63.
BokELeemELeeBR, et al.Role of the lipid membrane and membrane proteins in tau pathology. Front Cell Dev Biol2021; 9: 653815.
64.
ChanRBOliveiraTGCortesEP, et al.Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem2012; 287: 2678–2688.
65.
GrimmMOGrimmHSPätzoldAJ, et al.Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol2005; 7: 1118–1123.
66.
ZlokovicBV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci2011; 12: 723–738.
67.
ChrastRSaherGNaveKA, et al.Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. J Lipid Res2011; 52: 419–434.
68.
SuHRustamYHMastersCL, et al.Characterization of brain-derived extracellular vesicle lipids in Alzheimer's disease. J Extracell Vesicles2021; 10: e12089.
69.
HeXHuangYLiB, et al.Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging2010; 31: 398–408.
70.
KornhuberJMuehlbacherMTrappS, et al.Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One2011; 6: e23852.
71.
LiDMisialekJRJingM, et al.Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study. Am J Clin Nutr2020; 111: 1252–1258.
72.
ShenYWeiCTaishiY, et al.Association between the circulating very long-chain saturated fatty acid and cognitive function in older adults: findings from the NHANES. BMC Public Health2024; 24: 1061.
73.
PalaviciniJPWangCChenL, et al.Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A(2) in a spatial-specific manner. Acta Neuropathol Commun2017; 5: 56.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
